{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:46:29Z","timestamp":1792079189893,"version":"4.4.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00774-020-01087-0","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T06:03:13Z","timestamp":1580796193000},"page":"141-144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR"],"prefix":"10.1007","volume":"38","author":[{"name":"the Subcommittee for CTIBL in the JSBMR","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3610-3469","authenticated-orcid":false,"given":"Seiji","family":"Fukumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Soen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Matsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Terauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitsugu","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"key":"1087_CR1","doi-asserted-by":"publisher","first-page":"75646","DOI":"10.18632\/oncotarget.17980","volume":"8","author":"L Cianferotti","year":"2017","unstructured":"Cianferotti L, Bertoldo F, Carini M, Kanis JA, Lapini A, Longo N, Martorana G, Mirone V, Reginster JY, Rizzoli R, Brandi ML (2017) The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation. Oncotarget 8:75646\u201375663","journal-title":"Oncotarget"},{"key":"1087_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jama.2009.50","volume":"301","author":"D Bliuc","year":"2009","unstructured":"Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513\u2013521","journal-title":"JAMA"},{"key":"1087_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1186\/s12885-015-1843-3","volume":"15","author":"A Wang","year":"2015","unstructured":"Wang A, Obertova Z, Brown C, Karunasinghe N, Bishop K, Ferguson L, Lawrenson R (2015) Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand. BMC Cancer 15:837","journal-title":"BMC Cancer"},{"key":"1087_CR4","volume-title":"A guideline for the prevention and treatment of osteoporosis","author":"Committee for the preparation of a guideline for the prevention and treatment of osteoporosis","year":"2015","unstructured":"Committee for the preparation of a guideline for the prevention and treatment of osteoporosis  (2015) A guideline for the prevention and treatment of osteoporosis. Life Science Publishing Co., Ltd, Tokyo"},{"key":"1087_CR5","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/bjc.2016.314","volume":"115","author":"E Colzani","year":"2016","unstructured":"Colzani E, Clements M, Johansson AL, Liljegren A, He W, Brand J, Adolfsson J, Fornander T, Hall P, Czene K (2016) Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study. Brit J Cancer 115:1400\u20131407","journal-title":"Brit J Cancer"},{"key":"1087_CR6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2013.0215","volume":"11","author":"JR Gralow","year":"2013","unstructured":"Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar R, Litsas G, McKay R, Podoloff DA, Srinivas S, Van Poznak CH (2013) NCCN Task Force Report: bone health in cancer care. J Natl Compr Cancer Netw 11:S1\u2013S50","journal-title":"J Natl Compr Cancer Netw"},{"key":"1087_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","volume":"7","author":"P Hadji","year":"2017","unstructured":"Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML et al (2017) Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 7:1\u201312","journal-title":"J Bone Oncol"},{"key":"1087_CR8","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00198-019-04975-y","volume":"30","author":"WD Leslie","year":"2019","unstructured":"Leslie WD, Martineau P, Bryanton M, Lix LM (2019) Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study. Osteoporos Int 30:1445\u20131453","journal-title":"Osteoporos Int"},{"key":"1087_CR9","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/cncr.26313","volume":"118","author":"AM Brufsky","year":"2012","unstructured":"Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, Jin L, Warsi G, Argonza-Aviles E, Hohneker J, Ericson SG, Perez EA (2012) Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 118:1192\u20131201","journal-title":"Cancer"},{"key":"1087_CR10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mds277","volume":"24","author":"R Coleman","year":"2013","unstructured":"Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, von Minckwitz G, Sleeboom HP, Forbes J, Barrios C, Frassoldati A, Campbell I, Paija O, Martin N, Modi A, Bundred N (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 24:398\u2013405","journal-title":"Ann Oncol"},{"key":"1087_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Hern\u00e1ndez Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C, Denosumab HALT Prostate Cancer Study Group (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745\u2013755","journal-title":"N Engl J Med"},{"key":"1087_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a muticentre, randomized, double-blind, placebo-controlled trial. Lancet 386:433\u2013443","journal-title":"Lancet"},{"key":"1087_CR13","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1002\/cncr.24404","volume":"115","author":"T Satoh","year":"2009","unstructured":"Satoh T, Kimura M, Matsumoto K, Tabata K, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S (2009) Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. Cancer 115:3468\u20133474","journal-title":"Cancer"},{"key":"1087_CR14","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10549-012-1973-0","volume":"133","author":"S Takahashi","year":"2012","unstructured":"Takahashi S, Iwase T, Kohno N, Ishikawa T, Taguchi T, Takahashi M, Horiguchi J, Nakamura S, Hozumi Y, Fukunaga M, Noguchi S (2012) Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results. Breast Cancer Res Treat 133:685\u2013693","journal-title":"Breast Cancer Res Treat"},{"key":"1087_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00774-018-0917-0","volume":"37","author":"K Nakatsukasa","year":"2019","unstructured":"Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T (2019) Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer. J Bone Miner Metab 37:301\u2013306","journal-title":"J Bone Miner Metab"},{"key":"1087_CR16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s12282-018-0896-y","volume":"26","author":"K Nakatsukasa","year":"2019","unstructured":"Nakatsukasa K, Koyama H, Ouchi Y, Ono H, Sakaguchi K et al (2019) Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results. Breast Cancer (Tokyo, Japan) 26:106\u2013112","journal-title":"Breast Cancer (Tokyo, Japan)"},{"key":"1087_CR17","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.2147\/TCRM.S167579","volume":"14","author":"K Nakatsukasa","year":"2018","unstructured":"Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T (2018) Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study. Ther Clin Risk Manag 14:1213\u20131218","journal-title":"Ther Clin Risk Manag"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01087-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-020-01087-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01087-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T01:19:19Z","timestamp":1612315159000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-020-01087-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1087"],"URL":"https:\/\/doi.org\/10.1007\/s00774-020-01087-0","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,4]]},"assertion":[{"value":"11 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S.F. has received research grants from Astellas Pharma and Teijin Pharma. S.S. has received consulting fees, speaking fees, and\/or honoraria from Asahi Kasei Pharma, Astellas Pharma, Chugai Pharmaceutical, Daiichi-Sankyo, Eisai, Eli Lilly Japan, MSD, Ono Pharmaceutical, Pfizer, Takeda Pharmaceutical and Teijin Pharma. T.T. received research donation and lecture fee from Daiichi Sankyo. S.H. has received research grants and honoraria from Astellas pharma, Takeda Pharmaceutical, Astrazeneka and Sanofi. T.S. has received research grants from Astellas Pharma, Eisai, Daiichi-Sankyo, Chugai Pharmaceutical and Eli Lilly Japan, as well as lecture and\/or consulting fees from Asahi Kasei Pharma and Daiichi-Sankyo. T.M. has received consulting fees from Chugai Pharmaceutical, Amgen Astellas Biopharma, Teijin Pharma and Daiichi-Sankyo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}